» Articles » PMID: 34859062

Potential Mechanism of Dingji Fumai Decoction Against Atrial Fibrillation Based on Network Pharmacology, Molecular Docking, and Experimental Verification Integration Strategy

Overview
Date 2021 Dec 3
PMID 34859062
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Dingji Fumai Decoction (DFD), a traditional herbal mixture, has been widely used to treat arrhythmia in clinical practice in China. However, the exploration of the active components and underlying mechanism of DFD in treating atrial fibrillation (AF) is still scarce. Compounds of DFD were collected from TCMSP, ETCM, and literature. The targets of active compounds were explored using SwissTargetPrediction. Meanwhile, targets of AF were collected from DrugBank, TTD, MalaCards, TCMSP, DisGeNET, and OMIM. Then, the H-C-T-D and PPI networks were constructed using STRING and analyzed using CytoNCA. Meanwhile, VarElect was utilized to detect the correlation between targets and diseases. Next, Metascape was employed for systematic analysis of the mechanism of potential targets and protein complexes in treating AF. AutoDock Vina, Pymol, and Discovery Studio were applied for molecular docking. Finally, the main findings were validated through molecular biology experiments. A total of 168 active compounds and 1,093 targets of DFD were collected, and there were 89 shared targets between DFD and AF. H-C-T-D network showed the relationships among DFD, active compounds, targets, and AF. Three functional protein complexes of DFD were extracted from the PPI network. Further systematic analysis revealed that the regulation of cardiac oxidative stress, cardiac inflammation, and cardiac ion channels were the potential mechanism of DFD in treating AF. Addtionally, molecular docking verified the interactions between active compounds and targets. Finally, we found that DFD significantly increased the level of SIRT1 and reduced the levels of ACE, VCAM-1, and IL-6. DFD could be utilized in treating AF through a complicated mechanism, including interactions between related active compounds and targets, promoting the explanation and understanding of the molecular biological mechanism of DFD in the treatment of AF.

Citing Articles

Synthesis, characterization, and mechanistic insights into the enhanced anti-inflammatory activity of baicalin butyl ester via the PI3K-AKT pathway.

Du H, Li Z, Su L, He Z, Tan X, Hou F Front Pharmacol. 2024; 15:1417372.

PMID: 39104394 PMC: 11298432. DOI: 10.3389/fphar.2024.1417372.


Immune landscape and regulatory mechanisms in human atherosclerotic coronary plaques: Evidence from single-cell and bulk transcriptomics.

Liang W, Liao H, Liang B Heliyon. 2023; 9(9):e19392.

PMID: 37674826 PMC: 10477495. DOI: 10.1016/j.heliyon.2023.e19392.


The application and mechanism of Chinese medicine in the upstream treatment of atrial fibrillation.

Liu M, Mao C, Zhao F, Chen Z, Wang X Front Cardiovasc Med. 2023; 10:1229021.

PMID: 37608811 PMC: 10441233. DOI: 10.3389/fcvm.2023.1229021.


Guanxin V Relieves Ventricular Remodeling by Inhibiting Inflammation: Implication from Virtual Screening, Systematic Pharmacology, Molecular Docking, and Experimental Validation.

Liang B, Zhang X, Gu N Chin J Integr Med. 2023; 29(12):1077-1086.

PMID: 37528325 DOI: 10.1007/s11655-023-3642-z.


ETCM v2.0: An update with comprehensive resource and rich annotations for traditional Chinese medicine.

Zhang Y, Li X, Shi Y, Chen T, Xu Z, Wang P Acta Pharm Sin B. 2023; 13(6):2559-2571.

PMID: 37425046 PMC: 10326295. DOI: 10.1016/j.apsb.2023.03.012.


References
1.
Liang B, Zhao Y, Gu N . Letter by Liang et al Regarding Article, "Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage". Stroke. 2020; 51(6):e111. DOI: 10.1161/STROKEAHA.120.029434. View

2.
Sinner M, Pfeufer A, Akyol M, Beckmann B, Hinterseer M, Wacker A . The non-synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of KCNH2 (HERG). Eur Heart J. 2008; 29(7):907-14. DOI: 10.1093/eurheartj/ehm619. View

3.
Serezani C, Ballinger M, Aronoff D, Peters-Golden M . Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol. 2008; 39(2):127-32. PMC: 2720142. DOI: 10.1165/rcmb.2008-0091TR. View

4.
Daina A, Michielin O, Zoete V . SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017; 7:42717. PMC: 5335600. DOI: 10.1038/srep42717. View

5.
Wang J, Ye Q, Bai S, Chen P, Zhao Y, Ma X . Inhibiting microRNA-155 attenuates atrial fibrillation by targeting CACNA1C. J Mol Cell Cardiol. 2021; 155:58-65. DOI: 10.1016/j.yjmcc.2021.02.008. View